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Introduction
Staphylococcus aureus infection and drug resistance 
problems have caused increasing public health prob-
lems. The increase in antimicrobial resistance coupled 
with intracellular infection makes this bacteria the 
third-largest threat to human health according to the 
WHO (Lowy 1998; Demon et al. 2012). MRSA is of par-
ticular concern because of its ability to spread exten-
sively and rapidly, along with its multi-drug resistance 
to β-lactam and aminoglycoside antibiotics (Boucher 
et al. 2009; Kolendi 2010). MRSA infection is always 
associated with chronic or recurrent infections, includ-
ing osteomyelitis, pulmonary infection, and endocardial 
inflammation (Que et al. 2005). In China, almost 10% 
of S. aureus clinical isolates were considered resistant 
to penicillin in recent years (Hu et al. 2016; Chen et al. 
2017). Several new targets have been discovered and 
addressed in recent drugs, including ClpP protease 
and FtsZ of the cell division machinery. Resistance 
can be modified and inactivated by enzymatic drugs, 
enzymatic modification of drug-binding sites, drug 
efflux, and the others. Studies on the resistance of the 
current antibiotics have been reported also using drug 
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A b s t r a c t
This study explored a potential treatment against methicillin-resistant Staphylococcus aureus (MRSA) infections that combines thioridazine 
(TZ), an efflux pump inhibitor, and miconazole (MCZ), an autolysis inducer, with the anti-microbial drug cloxacillin (CXN). In vitro, the 
combination treatment of TZ and MCZ significantly reduced 4096-fold (Σ (FIC) = 0.1 – 1.25) the MIC value of CXN against S. aureus. 
In vivo, the combination therapy significantly relieved breast redness and swelling in mice infected with either clinical or standard strains 
of S. aureus. Meanwhile, the number of bacteria isolated from the MRSA135-infected mice decreased significantly (p = 0.0427 < 0.05) after 
the combination therapy when compared to monotherapy. Moreover, the number of bacteria isolated from the mice infected with a refer-
ence S. aureus strain also decreased significantly (p = 0.0191 < 0.05) after the combination therapy when compared to monotherapy. The 
pathological changes were more significant in the CXN-treated group when compared to mice treated with a combination of three drugs. 
In addition, we found that combination therapy reduced the release of the bacteria-stimulated cytokines such as IL-6, IFN-γ, and TNF-α. 
Cytokine assays in serum revealed that CXN alone induced IL-6, IFN-γ, and TNF-α in the mouse groups infected with ATCC 29213 
or MRSA135, and the combination of these three drugs significantly reduced IL-6, IFN-γ, and TNF-α concentrations. Also, the levels of 
TNF-α and IFN-γ in mice treated with a combination of three drugs were significantly lower than in the CXN-treated group. Given the 
synergistic antibacterial activity of CXN, we concluded that the combination of CXN with TZ, and MCZ could be developed as a novel 
therapeutic strategy against S. aureus.
K e y  w o r d s: Staphylococcus aureus, mastitis, thioridazine (TZ), miconazole (MCZ), cloxacillin (CXN), combination therapy
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combinations (Foster et al. 2017). Several synergistic 
combinations of small molecules and antibiotics have 
also been provided to treat S. aureus infection by revers-
ing the resistance mechanisms, attenuating S. aureus 
virulence and/or interfering with quorum sensing 
(Vermote et al. 2017). Thus, the urgency is required in 
the development of the new strategies for antimicrobial 
drug combinations against MRSA.
One novel strategy is to utilize helper compounds 
in combination with traditional antibiotics. Helper 
compounds are drugs approved for other therapeutic 
purposes that also possess antibacterial activity (Dickey 
et al. 2017). Thioridazine (TZ) is primarily an anti-
psychotic drug and also functions as an efflux pump 
inhibitor, which can be used as a helper compound 
(Klitgaard et al. 2008; Pule et al. 2016). Several in vitro 
studies have shown that TZ significantly increases the 
susceptibility of MRSA to β-lactam antibiotics (Poulsen 
et al. 2013). It has been shown that cytoderm synthe-
sis and autolysis are linked since the inhibition of the 
former activates the latter. Thus, the destruction of 
the cytoderm is an important step in the bactericidal 
process of penicillin and other antibiotics (Zore et al. 
2011). Miconazole (MCZ) is an antifungal drug that 
is considered as an autolysis inducer, which causes 
a release of cellular K+ at low concentrations, and MCZ 
at the minimum inhibitory concentration (MIC) showed 
a certain antibacterial effect on clinically isolated MRSA 
(Falk et al. 2010). In our study, we aimed to suppress 
the multiple drug resistance of MRSA by combining 
cloxacillin (CXN) with an autolysis inducer MCZ and 
an efflux pump inhibitor TZ.
The previous studies have shown that the innate 
immune response, including pattern recognition recep-
tors (PRR), was activated upon infection with S. aureus 
(Elazar et al. 2010). The release of cytokines is an impor-
tant indicator for the evaluation of antibiotics. When 
inoculated with S. aureus, immune cells produce the 
inflammatory cytokines such as tumor necrosis factor-α 
(TNF-α), interleukin 1β (IL-1β), and interleukin  6 
(IL-6) in high concentrations (Chen et al. 2017). 
S. aureus may also stimulate nuclear factor-ĸB inhibi-
tor (IKB), nuclear factor-ĸB (NF-KB), and mitogen-
activated protein kinase phosphorylation (Gao et al. 
2015). The previous studies have shown that TNF-α 
is the earliest and primary endogenous mediator and 
plays crucial role in both inflammatory and neuro-
pathic hyperalgesia (Zhang et al. 2007). In these stud-
ies, TNF-α and IL-6 after infection were released at 
high concentrations for 24 h, and there was no time 
gradient for IFN-γ detection after infection, which was 
consistent with previous reports (Trigo et al. 2009; Hu 
et al. 2010). In the studies on the mechanism of action 
of antibiotics, the level of cytokines was measured 
at 12–24 h (Wei W et al. 2009; Fu Y et al. 2014). The 
inflammatory cells including macrophages regulate 
inflammatory responses by the induction of significant 
inflammation and release of inflammatory cytokines 
(IL-1β, IL-6, and TNF-α) and chemokines (Kim et al. 
2015) at the high concentrations.
Our study is the first to explore the combination of 
TZ, MCZ, and CXN in the treatment of mastitis using 
a mouse model to provide a basis for subsequent com-
bined antibacterial therapy.
Experimental
Materials and Methods
Ethics statement. The BALB/c mice were housed 
in micro-isolator cages and received food and water 
freely. The laboratory temperature was 24 ± 1°C, and 
relative humidity was 40–80%. All animal studies 
were conducted according to the experimental prac-
tices and standards approved by the Animal Welfare 
and Research Ethics Committee at Jilin University 
(no: IZ-2009-008). The protocols were reviewed and 
approved by the committee. All animal studies were 
performed under isoflurane anesthesia, and every effort 
was made to minimize suffering.
Strains and growth conditions. S. aureus was 
obtained from the China Type Culture Collection 
(CTCC) (American Type Culture Collection [ATCC] 
29213), and S. aureus isolates were derived from sub-
clinical mastitis. The three antimicrobial agents used 
were CXN, MCZ (Yeyuan, Shanghai China), and TZ 
(MedChemexpress).
Antimicrobial susceptibility testing. To determine 
the MIC values for CXN, TZ, and MCZ against S. aureus 
a microdilution assay was performed according to the 
CLSI (formerly NCCLS) guidelines. The determination 
of the MIC of CXN for the mastitis isolates of S. aureus 
was performed using the Mueller-Hinton agar dilution 
assay according to the CLSI guidelines (CLSI 2008). 
Plates were incubated at 35–38°C for 16–20 h.
Interpretation of synergy tests. The synergy test 
was performed in a 96-well microtiter plate containing 
two or three antimicrobial agents that were distributed 
in a two- or three-fold dilution on the day of the assay 
in a checkerboard pattern. Each well contained 0.1 ml 
of an individual antimicrobial composition or broth 
control. The final inoculate concentration was main-
tained at 3–5 × 105 CFU/ml. The plate was incubated for 
20–24 h, and the MIC value was determined. S. aureus 
ATCC 29213 was used as the quality control strain.
For the first clear well in each row of the microtitre 
plate containing both antimicrobial agents, the frac-
tional inhibitory concentration (FIC) of each agent was 
calculated as follows:
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FIC of drug A (FICA) = MIC of drug A in combina-
tion / MIC of drug A alone
FIC of drug B (FICB) = MIC of drug B in combina-
tion / MIC of drug B alone
The summation of both FICs (Σ FIC) in each well 
(FICI = Σ FIC = FICA + FICB) was used to classify the 
combination of antimicrobial agents at the given con-
centrations as synergistic (Σ FIC, ≤ 0.5), partially syn-
ergistic (Σ FIC, > 0.5 and ≤ 1.0), indifferent (Σ FIC, > 1 
and ≤ 4), or antagonistic (Σ FIC, > 4) (Zore et al. 2011).
Using three-dimensional checkerboard microdilu-
tion with CXN, TZ, and MCZ the combined concen-
trations of each antibiotic showed synergy when their 
sum, FICI (Σ FICs) was lower than 1.0.
Mouse S. aureus mastitis model. The S. aureus mas-
titis mouse model has been used to investigate the novel 
prevention and treatment methods for S. aureus mas-
titis, as reported previously. Briefly, the mice weighed 
approximately 50 g at the beginning of the experiment. 
The pups were weaned 1–2 h before bacterial inocula-
tion of the mammary glands. A mixture of oxygen and 
isoflurane (2–3%) was inhaled to anesthetize the lactat-
ing mice. A syringe with a 32-gauge blunt needle was 
used to inoculate both L4 (on the left) and R4 (on the 
right) glands of the fourth abdominal mammary gland 
pair, with approximately 107 CFU of S. aureus. A total 
of 18 mice were used for each mice group infected 
with a single strain of S. aureus, either ATCC 29213 
or MRSA135. The 18 mice of each group were divided 
into the following groups, with three mice in each 
group: blank (I), infection control (II), MCZ mono-
therapy (III), TZ monotherapy (IV), CXN monother-
apy (V), and CXN + TZ + MCZ treatment (VI) groups. 
The mice were observed for 24 h following infection 
before treatment was initiated, and then the results were 
obtained after 72 h of treatment in each drug group. 
In in vivo experiment, the concentration of cloxacil-
lin was 20 mg/kg/d, thioridazine – 16 mg/kg/d, and 
miconazole – 11 mg/kg/d in the single-agent treatment 
group. In the combination treatment group the con-
centration of: cloxacillin was 0.75 mg/kg/d, thioridazine 
– 12 mg/kg/d, and miconazole – 1.5 mg/kg/d.
Cytokines in the mastitis mouse model. At 24 h 
after S. aureus inoculation the animal blood was cen-
trifuged. Cytokines were detected by the double sand-
wich enzyme-linked immunosorbent assay technique. 
Different groups were compared using an independ-
ent samples t-test, and a paired samples t-test was used 
to analyze any significant differences in the data that 
originated from the same group at different time points 
(Moon et al. 2007).
Antimicrobial susceptibility testing. The MIC of 
CXN against 47 strains of S. aureus was determined, and 
the values ranged from 4 to 512 μg/ml. The MIC value 
of CXN against S. aureus ATCC 29213 was 4 μg/ml 
and that of MRSA135 was 256 μg/ml. The drug suscep-
tibility results showed that 23 strains of S. aureus were 
resistant to CXN, while 24 strains of S. aureus were sen-
sitive to CXN. The MIC of TZ for 47 strains of S. aureus 
was determined, ranging from 16 μg/ml to 64 μg/ml. 
The MIC value of TZ for S. aureus ATCC 29213 was 
16 μg/ml and that of MRSA135 μg/ml was 32 μg/ml. 
The MIC of MCZ for 47 strains of S. aureus was deter-
mined, and the values ranged from 1 μg/ml to 8 μg/ml. 
The MIC value of MCZ for S. aureus ATCC 29213 was 
4 μg/ml and that of MRSA135 was 4 μg/ml (Table I).
Drug synergy results against S. aureus isolates. 
The FICI index, used as a predictor of synergy, was 
evaluated using the TZ and MCZ agents combined with 
CXN (Table II). The results showed that both the com-
bination of the two drugs and the combination of the 
three drugs reduced the MIC value of the drugs to vary-
ing degrees. Anti-S. aureus activity of two drugs, CXN 
and TZ, was shown in Table III. Among the 47 strains 
tested, the combined FICI ranged from 0.14 to 1.13, 
of which 24 strains had synergistic effects (0.14–0.5), 
13  strains had partial synergistic effects (0.56–0.75), 
and 10 strains had an unrelated effect (1.06–1.25). Anti-
S. aureus activity of a combination of CXN and MCZ 
was reported in Table IV. Among the 47 strains tested, 
the combined FICI ranged from 0.14 to 2.25, of which 
15 had synergistic effects (0.14–0.5), 15 had partial syn-
ergistic effects (0.51–1), and 17 had irrelevant effects 
(1.03–2.25). The activity of a combination of CXN, TZ, 
and MCZ against S. aureus MRSA strains was shown 
in Table V. The FICI ranged from 0.19 to 0.75 among 
Cloxacillin  4–512 16 512
Thioridazine 16–64 32 64
Miconazole  1–8 4 8
Table I
The MICs values of individual antimicrobial agents against
Staphylococcus aureus isolates.
MIC – minimum inhibitory concentration
Antimicrobial
agents
MIC (μg/ml)
Range 50% 90%
Cloxacillin Thioridazine 0.125–512 16 512
 Miconazole 0.25–512  4 512
 Thioridazine 0.000972–16  0.5 8 + Miconazole
Table II
Summary of thioridazine, miconazole and cloxacillin activity
in combination (expressed as the MIC value) against
Staphylococcus aureus strains.
MIC – minimum inhibitory concentration
Antimicrobial
agents
MIC (μg/ml)
Range 50% 90%
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Table III
The activity of the combination of cloxacillin and thioridazine
against Staphylococcus aureus strains in vitro.
Strain FICI
MRSA14 0.38
MRSA15 0.63
MRSA16 0.75
MRSA20 0.25
MRSA21 0.50
MRSA22 0.63
MRSA25 0.31
MRSA29 0.19
MRSA30 1.06
MRSA64 0.25
MRSA65 0.25
MRSA75 1.13
MRSA76 1.13
MRSA92 0.31
MRSA94 0.19
MRSA97 0.25
MRSA98 0.19
MRSA125 0.27
MRSA126 0.50
MRSA134 0.16
MRSA135 0.16
MRSA142 0.63
MRSA162 0.38
ATCC 29213 0.28
MSSA10 0.31
MSSA13 0.56
MSSA14 0.63
MSSA31 0.63
MSSA36 0.38
MSSA41 0.63
MSSA42 0.56
MSSA44 0.38
MSSA50 0.38
MSSA51 0.14
MSSA54 0.38
MSSA56 0.63
MSSA62 0.63
MSSA65 0.63
MSSA66 1.13
MSSA67 1.13
MSSA68 1.13
MSSA70 1.13
MSSA72 1.06
MSSA73 0.63
MSSA78 1.25
MSSA79 1.25
MSSA80 0.25
See FICI criteria for details.
MRSA14 0.63
MRSA15 0.75
MRSA16 0.38
MRSA20 0.31
MRSA21 0.31
MRSA22 2.25
MRSA25 0.53
MRSA29 2.13
MRSA30 0.26
MRSA64 0.14
MRSA65 0.26
MRSA75 1.00
MRSA76 1.13
MRSA92 0.26
MRSA94 0.51
MRSA97 0.52
MRSA98 0.26
MRSA125 0.50
MRSA126 1.50
MRSA134 1.50
MRSA135 0.27
MRSA142 1.01
MRSA162 0.63
ATCC 29213 0.50
MSSA10 0.56
MSSA13 0.31
MSSA14 2.00
MSSA31 1.13
MSSA36 2.02
MSSA41 1.50
MSSA42 0.27
MSSA44 1.06
MSSA50 1.03
MSSA51 1.00
MSSA54 1.50
MSSA56 1.00
MSSA62 1.50
MSSA65 1.03
MSSA66 0.53
MSSA67 0.31
MSSA68 0.53
MSSA70 0.52
MSSA72 0.28
MSSA73 1.03
MSSA78 1.06
MSSA79 0.56
MSSA80 0.56
Table IV
The activity of the combination of cloxacillin and miconazole
against Staphylococcus aureus strains in vitro.
See FICI criteria for details.
Strains FICI
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the 23 strains tested, of which 20 strains had synergis-
tic effects (0.19–0.5), and three isolates have partial 
synergy (0.63–0.75). The activity of a combination of 
CXN, TZ, and MCZ against S. aureus MSSA strain 
(Table VI) showed that the FICI ranged from 0.1 to 1.25 
for 23 strains tested, 19 of which had synergistic effects 
(0.1–0.5), one has a partial synergistic effect (0.69), and 
three strains have an unrelated effect (1.09–1.25). As 
the results of the synergistic tests, the concentration 
of each drug can be lowered. The in vivo dose of the 
compounds administered were referred to the ratio of 
the MIC value at synergistic combination (cloxacil-
lin : thioridazine : miconazole = 0.25 μg/ml : 4 μg/ml : 
0.50 μg/ml) as it was obtained by checkerboard assay in 
vitro, where the synergistic ratio of cloxacillin : thiori-
dazine : miconazole was 1 : 16 : 2. We also, referred to the 
dose of these compounds when they were single-admin-
istered to mouse or calculated from other animal stud-
ies already reported in vivo (cloxacillin ≤ 50 mg/kg/d, 
thioridazine ≤ 16 mg/kg/d, miconazole ≤ 20 mg/kg/d) 
(Hendricks et al. 2003; Choi et al. 2012). Finally, we cal-
culated the corresponding dose of these compounds 
to be single-administered or in combination with ani-
mal experiments in vivo. The in vivo concentrations of 
three drugs in a combination treatment was as follows: 
cloxacillin (0.75 mg/kg/d) : thioridazine (12 mg/kg/d) : 
miconazole (1.5 mg/kg/d).
Statistical analysis. Comparisons of mean values 
from three experiments were statistically evaluated by 
analysis of variance, followed by the One-Way ANOVA 
MRSA14 512 32 2 4 4 0.25 0.26
MRSA15 512 32 2 2 4 0.25 0.25
MRSA16 512 16 4 1 4 0.25 0.31
MRSA20 256 32 2 0.25 4 0.25 0.25
MRSA21 128 16 4 0.5 4 0.25 0.32
MRSA22 64 32 4 0.25 4 0.50 0.25
MRSA25 512 16 2 0.5 4 0.50 0.50
MRSA29 256 64 4 4 4 0.50 0.20
MRSA30 512 64 4 0.5 4 0.50 0.19
MRSA64 512 32 8 8 4 0.50 0.20
MRSA65 512 32 4 0.5 4 0.50 0.25
MRSA75 512 32 2 0.5 4 0.50 0.38
MRSA76 512 32 4 8 4 0.50 0.27
MRSA92 512 16 4 0.0078 4 0.50 0.38
MRSA94 512 32 2 0.0078 4 0.50 0.38
MRSA97 256 32 2 0.0156 4 0.50 0.38
MRSA98 512 32 4 0.0078 4 0.50 0.25
MRSA125 256 16 2 0.5 4 0.50 0.50
MRSA126 256 16 1 1 4 0.50 0.75
MRSA134 512 32 1 0.0078 4 0.50 0.63
MRSA135 256 32 4 0.25 4 0.50 0.25
MRSA142 512 32 1 2 4 0.50 0.63
MRSA162 512 32 4 16 4 0.50 0.28
ATCC 29213 4 16 4 0.0156 4 0.50 0.38
Table V
The activity of the combination of cloxacillin, thioridazine, and miconazole against MRSA strains in vitro.
See FICI criteria for details.
MCZ – miconazole; TZ – thioridazine; CXN – cloxacillin;
FIC of drug A (FICA) = MIC of drug A in combination / MIC of drug A alone;
FIC of drug B (FICB) = MIC of drug B in combination / MIC of drug B alone;
Combination FIC (AB) = Σ FIC = FICA + FICB;
Synergistic (Σ FIC ≤ 0.5);
Partially synergistic (Σ FIC > 0.5 and ≤ 1.0);
Indifferent (Σ FIC > 1 and ≤ 4);
Antagonistic (Σ FIC > 4).
Strain
CXN TZCXNMCZTZ
MICs (Synergy)
FICI
MCZ
MICs (Single)
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Table VI
The activity of the combination of cloxacillin, thioridazine, and miconazole against MSSA strains in vitro.
Strain
CXN TZCXNMCZTZ
MICs (Synergy)
FICI
MCZ
MICs (Single)
See FICI criteria for details.
MCZ – miconazole; TZ – thioridazine; CXN – cloxacillin;
FIC of drug A (FICA) = MIC of drug A in combination / MIC of drug A alone;
FIC of drug B (FICB) = MIC of drug B in combination / MIC of drug B alone;
Combination FIC(AB) = Σ FIC = FICA + FICB;
Synergistic (Σ FIC ≤ 0.5);
Partially synergistic (Σ FIC > 0.5 and ≤ 1.0);
Indifferent (Σ FIC > 1 and ≤ 4);
Antagonistic (Σ FIC > 4).
MSSA10 16 64 4 4 4 0.25 0.38
MSSA13 8 64 8 8 4 0.25 1.09
MSSA14 8 32 2 8 4 0.25 1.25
MSSA31 16 32 2 4 4 0.25 0.50
MSSA36 16 32 1 0.015625 4 0.25 0.38
MSSA41 8 32 1 4 4 0.25 0.88
MSSA42 16 64 8 0.125 4 0.25 0.10
MSSA44 16 32 1 0.5 4 0.25 0.41
MSSA50 16 32 1 0.125 4 0.25 0.38
MSSA51 16 32 2 0.001975 4 0.25 0.25
MSSA54 16 16 2 0.0625 4 0.25 0.38
MSSA56 16 32 2 0.03125 4 0.25 0.25
MSSA62 16 32 2 0.0009715 4 0.25 0.25
MSSA65 16 32 2 0.125 4 0.25 0.26
MSSA66 16 32 4 4 4 0.25 0.44
MSSA67 16 32 4 8 4 0.25 0.69
MSSA68 16 32 4 16 4 0.25 1.19
MSSA70 16 32 4 0.015625 4 0.25 0.19
MSSA72 16 64 8 0.5 4 0.25 0.13
MSSA73 16 32 2 0.0625 4 0.25 0.25
MSSA78 8 16 2 0.03125 4 0.25 0.38
MSSA79 8 16 4 0.03125 4 0.25 0.32
MSSA80 16 32 4 0.0078125 4 0.25 0.19
ATCC 29213 4 16 4 0.0156 4 0.50 0.38
analysis. Differences with 2-sided p < 0.05 were con-
sidered statistically significant. All statistical analyses 
were performed using the GraphPad Prism 5 software 
(version 11.5; SPSS).
Results
Mouse mastitis treatment results. Two S. aureus 
mastitis mouse models were constructed, each injected 
with a single strain of S. aureus, either ATCC 29213 or 
the MRSA135 strain (Fig. 1A). Clinical observations 
showed that none of the mice in either the ATCC 29213 
or MRSA135 groups died during the experiment, and 
their mental states were normal. The areolas of both 
bacterial infection groups were swollen and red. The 
areolas in the MCZ or TZ monotherapy group were 
pale red and swollen, but there were no significant 
changes in the other groups. In the MRSA-infected 
groups, the mammary glands varied in color; those of 
the blank control group were milky white, those of the 
infection control group were purple, those of the MCZ 
or TZ treated group were red, those of a portion of the 
CXN treated group were red but most were milky white, 
and most were also milky white in the group treated 
with the combination of the three drugs (Fig. 1B). In 
the ATCC 29213-infected groups, the mammary glands 
varied in color; the blank control group had a normal 
mammary gland color, the infection control group had 
purple mammary glands, most of the glands in the 
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MCZ- and TZ-treated groups were red, and those of 
the CXN-treated and combination-treated groups were 
mostly milky white (Fig. 1C).
Histopathology of mammary tissue by the hematox-
ylin and eosin stain (H&E) was observed (Fig. 2A, and 
2B). No obvious pathological changes were found in 
the blank control group, which displayed normal acinar 
mammary glands and neat rows of acinar epithelial cells 
with prolactin. A large number of bacterial lumps and 
detached cells were seen in the infection control group, 
and both had red blood cell infiltrate observed in the 
interstitial space. The agglomerated cell mass was seen 
Fig. 1A i 1B. Clinical observations of mammary tissue of mouse infected with Staphylococcus aureus ATCC 29213
or MRSA135 before and after treatment with the drugs.
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in the acinus, and large numbers of lymphocyte infil-
trate were observed in the interstitium. In the MCZ or 
TZ monotherapy groups, epithelial cells were swollen, 
obvious bacterial masses were visible, and lymphocytes 
had infiltrated the stroma. Few lymphocytes and cer-
tain bacterial masses were observed in the CXN group. 
In the combination group, few lymphocytes and very 
few bacteria were visible, in addition to a lack of cell 
shedding. The results showed that, in addition to the 
known effect of CXN monotherapy, the combination 
of CXN, TZ, and MCZ has obvious therapeutic effects 
against infection by both strains of S. aureus tested. In 
the group treated with the combination of the three 
drugs, most of the pathological changes were milder 
than the CXN treatment group.
S. aureus count results. Colony counts from mice 
of the clinical strain MRSA135-infected group showed 
that the bacterial concentration was 6.96 × 107 CFU/ml 
without therapy. Following treatment, the bacterial 
concentration in mice of the MCZ-treatment group 
was 2.23 × 107 CFU/ml; in the TZ-treatment group it 
was 1.73 × 107 CFU/ml; after CXN treatment it was 
3.20 × 106 CFU/ml (p = 0.0447 < 0.05), and after the 
combination therapy with CXN, TZ, and MCZ it was 
1.10 × 106 CFU/ml (p = 0.0427 < 0.05) (Fig. 3B). There 
was no significant difference between the CXN mono-
therapy- and the combination therapy groups (Fig. 3C). 
The colony counts after the mice were infected with 
the reference strain ATCC 29213 showed the follow-
ing: the bacterial concentration without therapy was 
2.34 × 105 CFU/ml; in the MCZ-treatment group it 
was 1.56 × 105 CFU/ml; in the TZ-treatment group 
it was 7.91 × 104 CFU/ml; after CXN treatment it 
was 1.17 × 104 CFU/ml (p = 0.0212 < 0.05); and after 
the combination therapy with CXN, TZ, and MCZ 
was 4.43 × 103 CFU/ml (p = 0.0191 < 0.05) (Fig. 3A). 
The diffe rence between the CXN monotherapy and 
the three-drug treatment groups was significant 
(p = 0.0040 < 0.01) (Fig. 3D).
Cytokine detection in a mouse model of mastitis. 
Serum supernatants were assayed for TNF-α, IL-6 and 
IFN-γ levels using an ELISA kit (Fig. 4). The cytokines 
measured in the sera of mice infected with ATCC 29213 
(the ATCC 29213 infected group) were as follows: the 
infected group had significantly increased levels of 
TNF-α, IL-6, and IFN-γ when compared to those in 
the control group (p = 0.0260, p = 0.0348, p < 0.0001, 
respectively) (Fig. 4A, 4C, and 4E). There was no sig-
nificant difference in TNF-α, IL-6, and IFN-γ levels 
between mice treated with MCZ when compared with 
those of the control group. The levels of IL-6 and IFN-γ 
in the TZ-treated group were significantly lower than 
those in the ATCC 29213-infected group (p = 0.0176, 
p = 0.0046), but there was no significant difference in 
TNF-α levels. The levels of TNF-α, IL-6, and IFN-γ in 
the CXN-treated group were significantly lower than 
those in the infected group (p = 0.0016, p = 0.0245, 
p < 0.0001, respectively). The levels of TNF-α, IL-6, 
and IFN-γ in the group of mice treated with three 
drugs together were significantly lower than those in 
Fig. 1C. Clinical observations of mammary tissue of mouse infected with Staphylococcus aureus ATCC 29213
or MRSA135 before and after treatment with the drugs.
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the ATCC 29213-infected group (p = 0.0004, p = 0.0136, 
p < 0.0001). The levels of TNF-α and IFN-γ in the group 
of mice treated with three drugs together were signifi-
cantly lower than those in the ATCC 29213-infected 
group (p = 0.0084, p = 0.0280). The cytokine results in 
the MRSA135-infected mice (the MRSA135-infected 
group) were as follows: the MRSA135-infected group 
had significantly higher levels of IL-6 and IFN-γ than 
those in the control group (p = 0.0185, p = 0.0148, 
respectively) (Fig. 4B, 4D, and 4F). The levels of TNF-α 
and IL-6 in the MCZ-treated group were not signifi-
cantly different from those the MRSA135-infected 
Fig. 2. Histopathological observations for each group of mice (control, infected, and treated with the drugs).
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group, but the IFN-γ levels were significantly decreased 
(p = 0.0434). There were no significant differences in 
TNF-α, IL-6, and IFN-γ levels in the TZ-treated group 
compared with those of the MRSA135-infected group. 
The levels of IL-6 and IFN-γ in the CXN-treated group 
were significantly lower than those the MRSA135-
infected group (p = 0.0191, p = 0.0262, respectively), 
but there was no significant difference in TNF-α levels. 
Fig. 3A i 3B
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The levels of TNF-α, IL-6, and IFN-γ in mice treated 
with the three drugs together were significantly lower 
than those of the MRSA135-infected group (p = 0.0230, 
p = 0.0051, p = 0.0060, respectively). The TNF-α levels in 
mice treated with the three drugs together were signifi-
cantly lower than those of the MRSA135-infected group 
(p = 0.0010). In summary, treatment with CXN alone 
or with the combination of three drugs was capable of 
inhibiting the expression of TNF-α and IL-6.
Discussion
A recent report indicated that developing of new 
natural compounds or combination therapies should 
be a focus on the fight against S. aureus (Celenza et al. 
2012; Dickey et al. 2017) Combinations of antibiotics 
have been previously used to treat bacterial infections, 
including pathogens that cannot be suppressed or killed 
by a single antibiotic or infection with a multiplicity of 
microbial species (Navon-Venezia et al. 2005). A sin-
gle antibiotic is hardly capable of killing bacteria that 
possess multiple drug resistance mechanisms against 
broad-spectrum β-lactams and aminoglycosides antibi-
otics (Wax 2008). However, bacteria can be inactivated 
through the joint use of a synergistically active antibac-
terial agent along with the antibiotic (Mascaretti 2003; 
Tegos and Mylonakis 2012). Combination therapy can 
improve the antibacterial effect and reduce the risk of 
drug resistance during treatment, thereby reducing 
drug toxicity (Tegos and Mylonakis 2012; Breser et al. 
2018). In addition, it has been found that when syn-
thetic peptides of host defense bind to conventional 
antibiotics, synergistic effects can reduce the concentra-
tion of antibiotics required to eradicate certain bacterial 
strains of interest (Rudilla et al. 2016). Alternatively, the 
two antimicrobial agents combination can also neutral-
ize the biofilm development (Hwang et al. 2013). How-
ever, the antibiotic enhancement remains a challenge, 
and clinical treatment of bovine mastitis also lacks pre-
clinical animal and clinical data to validate its utility 
(Tse et al. 2017). This study demonstrates that the drug 
combination provides good effects in the in vitro assays 
and in the in vivo treatment of mouse mastitis, and can 
provide a basis for clinical development. Following the 
CLSI recommendations, supplementary tests should be 
performed, even when the penicillin MIC (≤ 0.12 mg/l) 
is within the drug-sensitive range in vitro (CLSI 2015). 
The combination of TZ and β-lactam antibiotics may 
enhance efficacy against S. aureus as a synergistic effect. 
In this study, the results of in vivo experiments indi-
cated that the concentration of cloxacillin alone (20 mg/
kg/d) was higher than in the combination with the two 
other drugs (0.75 mg/kg/d), and the treatment effect 
was better for the combination of drugs. Thus, this 
study indicates the concentration of drugs that reduce 
drug resistance when used synergistically, providing 
some new ideas for drug resistance research.
Previous studies reported that TZ functions as an 
external pump inhibitor, and MCZ acts as an autolytic 
inducer against S. aureus (Pule et al. 2016). Therefore, we 
investigated these two drugs in combination with CXN 
to inhibit the resistance of S. aureus through the induc-
tion of bacterial autolysis, thus enhancing the antibacte-
rial effect of CXN. In this study, the drug susceptibility 
results showed that S. aureus had particular resistance to 
CXN. Again, the two drugs showed a synergistic effect 
in inhibiting S. aureus. The synergistic effect of CXN and 
MCZ was better that of CXN and TZ. The synergistic 
effect of the three drugs studied not only reduced the 
concentration of CXN required but also enhanced the 
antibacterial effect. Altogether, our results suggested that 
Fig. 3. The culture of Staphylococcus aureus isolated from each group of mice (control, infected, treated with the drugs).
 MCZ – miconazole; TZ – thioridazine; CXN – cloxacillin; MCZ + TZ + CXN – the combination of miconazole, thioridazine, cloxacillin. There was no 
significant difference between the cloxacillin-treated and three-drugs-treated mice (P = 0.5649). The * on the horizontal line indicates a significant dif-
ference analysis between the CXN group and the three-drug group.* P < 0.05, ** p < 0.01, *** p < 0.0001.
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treatment with a combination of TZ and CXN showed 
a stronger inhibitory effect against S. aureus in vitro 
when compared to the effect of CXN monotherapy. 
When TZ and CXN were used in combination, the MIC 
value was significantly reduced. In the checkerboard 
test, the FICI model is commonly used to determine 
Fig. 4. Drug effects on the cytokine level in mouse mastitis models.
(A) Serum IFN-γ level in mice infected with ATCC 29213; (B) Serum IFN-γ level in mice infected with MRSA135; (C) Serum IL-6 level in mice 
infected with ATCC 29213; (D) Serum IL-6 level in mice infected with MRSA135; (E) Serum TNF-α level in mice infected with ATCC 29213; 
(F) Serum TNF-α level in mice infected with MRSA135; MCZ – miconazole; TZ – thioridazine; CXN – cloxacillin; MCZ + TZ + CXN – combination 
of miconazole, thioridazine, cloxacillin. The * on the horizontal line indicates a significant difference analysis between the CXN group and the three-
drug group. * P < 0.05, **p < 0.01, ***p < 0.0001.
the synergy between anti-staphylococcal drugs. Moreo-
ver, the in vivo dosage of the administered combination 
compound was determined by the ratio of in vitro syner-
gistic combination of the MIC values, the single in vivo 
doses administered in mouse studies or calculated from 
the other animal studies already reported.
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